Anika Therapeutics Inc (ANIK) Holdings Reduced by Raymond James & Associates

Share on StockTwits

Raymond James & Associates trimmed its position in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 17.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,121 shares of the biotechnology company’s stock after selling 1,259 shares during the quarter. Raymond James & Associates’ holdings in Anika Therapeutics were worth $206,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Anika Therapeutics by 3.8% during the third quarter. BlackRock Inc. now owns 2,136,362 shares of the biotechnology company’s stock valued at $90,112,000 after purchasing an additional 78,532 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Anika Therapeutics by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 997,485 shares of the biotechnology company’s stock valued at $42,074,000 after purchasing an additional 19,916 shares during the period. Vanguard Group Inc boosted its stake in shares of Anika Therapeutics by 1.0% during the third quarter. Vanguard Group Inc now owns 861,569 shares of the biotechnology company’s stock valued at $36,340,000 after purchasing an additional 8,799 shares during the period. Vanguard Group Inc. boosted its stake in shares of Anika Therapeutics by 1.0% during the third quarter. Vanguard Group Inc. now owns 861,569 shares of the biotechnology company’s stock valued at $36,340,000 after purchasing an additional 8,799 shares during the period. Finally, AMI Asset Management Corp boosted its stake in shares of Anika Therapeutics by 1.3% during the fourth quarter. AMI Asset Management Corp now owns 322,062 shares of the biotechnology company’s stock valued at $10,825,000 after purchasing an additional 4,243 shares during the period. 89.82% of the stock is owned by institutional investors.

ANIK stock opened at $32.18 on Wednesday. The stock has a market capitalization of $456.62 million, a P/E ratio of 17.49, a PEG ratio of 2.63 and a beta of 1.40. Anika Therapeutics Inc has a 1-year low of $28.54 and a 1-year high of $47.09.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Thursday, February 21st. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.22. The firm had revenue of $27.00 million during the quarter, compared to the consensus estimate of $26.22 million. Anika Therapeutics had a return on equity of 10.54% and a net margin of 17.74%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. On average, research analysts anticipate that Anika Therapeutics Inc will post 1.22 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. TheStreet raised shares of Anika Therapeutics from a “c” rating to a “b-” rating in a research note on Friday, February 22nd. BidaskClub raised shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. ValuEngine raised shares of Anika Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 11th. Finally, First Analysis lowered shares of Anika Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $41.00 to $37.00 in a research note on Friday, February 22nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $40.00.

In other news, CEO Joseph G. Darling acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 28th. The stock was purchased at an average cost of $33.20 per share, for a total transaction of $33,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 22,436 shares of the company’s stock, valued at approximately $744,875.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond J. Land sold 4,000 shares of Anika Therapeutics stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $33.06, for a total value of $132,240.00. Following the completion of the sale, the director now owns 18,992 shares of the company’s stock, valued at $627,875.52. The disclosure for this sale can be found here. Insiders own 8.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Anika Therapeutics Inc (ANIK) Holdings Reduced by Raymond James & Associates” was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4299548/anika-therapeutics-inc-anik-holdings-reduced-by-raymond-james-associates.html.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Featured Story: How Do Investors Open a Backdoor Roth IRA?

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$3.37 Million in Sales Expected for Viveve Medical Inc  This Quarter
$3.37 Million in Sales Expected for Viveve Medical Inc This Quarter
Ren  Price Hits $0.0250 on Major Exchanges
Ren Price Hits $0.0250 on Major Exchanges
Viuly  1-Day Trading Volume Tops $218.00
Viuly 1-Day Trading Volume Tops $218.00
Bolenum  Price Hits $0.0000 on Major Exchanges
Bolenum Price Hits $0.0000 on Major Exchanges
Finjan Holdings Inc  Given Consensus Recommendation of “Strong Buy” by Analysts
Finjan Holdings Inc Given Consensus Recommendation of “Strong Buy” by Analysts
Align Technology  Issues Q2 2019 Earnings Guidance
Align Technology Issues Q2 2019 Earnings Guidance


© 2006-2019 Ticker Report